Tagged with AI

Taiwan Taiwan is, in many ways, a healthcare model for Asia. The island has had universal health coverage for over 30 years and Taiwan’s life expectancy today is almost 81 years, putting it behind only Japan, South Korea, and Singapore in its region. However, by the early 2020s, this rapidly ageing…

Taiwan Vincent Tong, Managing Director of MSD Taiwan, brings two decades of pharmaceutical expertise to his second tenure leading the organisation in Taiwan. Having first served in Taiwan in 2008, Tong has witnessed the market’s evolution from emerging economy to sophisticated healthcare innovator. His career spans multiple markets across Asia-Pacific and…

Taiwan Professor Pan Chyr Yang is a clinician-scientist with an MD and PhD in pulmonary medicine, holding joint appointments at Academia Sinica and former university leadership roles in National Taiwan University. Recognised for pioneering non-smoker lung cancer screening methodologies in Asia, he has established national surveillance programmes now adopted across the region.…

Spain The latest stories from Spain’s booming healthcare and life science industry. Spain still leads Europe for clinical trial numbers, while a recent meeting between Spanish PM Pedro Sánchez and Roche CEO Thomas Schinecker on a new manufacturing agreement speaks to global pharma’s continued focus on the country. In other news,…

Taiwan With its thriving innovation ecosystem and growing global visibility, Taiwan is fast emerging as one of Asia’s most dynamic biotechnology hubs. At the forefront of this transformation is Wallace Lin, Secretary-General of Taiwan Bio, who has spent his career bridging science, policy, and industry to strengthen the nation’s life sciences…

Taiwan Dr Chih-Kang Chiang, Director-General of the TFDA, shares how Taiwan is redefining regulation through science, transparency, and international collaboration. Combining his backgrounds in medicine, toxicology, and law, he leads efforts to strengthen patient safety, accelerate innovation in AI and regenerative medicine, and reinforce supply resilience. This conversation offers insight into…

France After two decades with AstraZeneca across Europe and the United States, Anne-Laure Dreno now leads the group’s French affiliate at a time of exceptional scientific and organisational momentum. In this conversation, she reflects on AstraZeneca France’s rapid growth, the country’s evolving research and access landscape, and the company’s pioneering commitment…

France Founded in 1973, IFIS stands at the intersection of education, industry, and public policy, shaping the capabilities that underpin France’s global health leadership. Evolving from its origins as a training fund manager into a multifaceted institution, IFIS today drives professional excellence across pharmaceuticals, medtech, and cosmetics, bridging technical expertise, digital…

Taiwan After more than two decades in Silicon Valley, Dr Jeng Her returned to Taiwan with a bold ambition: to help transform its emerging biotech sector into a globally recognised force in antibody innovation. As Founder and CEO of AP Biosciences, he has positioned the company at the forefront of bispecific…

Taiwan Dr Wen-Liang Huang, General Manager of Ever Supreme Biotechnology, brings over 40 years of clinical cardiology experience to biopharmaceutical leadership. Recruited by the company’s founder, his medical background informs the translation of cell therapy innovations into meaningful patient treatments. Under his guidance, Ever Supreme has become Taiwan’s pioneering cell therapy…

Taiwan Dr Chiu-Heng Chen (John), CEO of LaunXP, brings a unique perspective to oncology drug development shaped by his personal experience with cancer during his PhD in the UK. Holding advanced degrees from British and Taiwanese institutions in tumour oncology, he founded LaunXP in 2015 to bridge academia and clinical practice,…

USA The latest updates from the US healthcare and life sciences scene. Eli Lilly partners with Nvidia to build a supercomputer for faster drug discovery; Trump secures “most-favored-nation” pricing deals with AstraZeneca and EMD Serono; former FDA vaccine chief Peter Marks joins Lilly to head infectious diseases; Organon CEO Kevin Ali…